This article presents a novel class of chemically identical theranostic small-molecule prodrug conjugates (T-SMPDCs), [¹⁸/¹⁹F]F-TZ(PSMA)-LEGU-TLR7, for PSMA-targeted delivery and controlled release of toll-like receptor 7 (TLR7) agonists to elicit de novo immune response for cancer immunotherapy. The proof-of-concept biological evaluation presented demonstrates the potential of T-SMPDCs for cancer immunomodulatory therapies.

This paper was awarded a Nicholas and Anna Ricco Ethics Award for 2013. In this paper, the author explores the issue of academic integrity and the prevalence of cheating in academia, issues surrounding reform and preventative measures for dishonesty, and why some students still proudly pursue an honest education.